PMEF
KZR

Point72 Middle East FZE’s Kezar Life Sciences KZR Stock Holding History

Point72 Middle East FZE’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,752
Closed -$91.9K – 1676
2023
Q2 		$91.9K Buy
3,752
+1,324
+55% +$34.5K ﹤0.01% 1217
2023
Q1 		$76K Buy
+2,428
New +$140K ﹤0.01% 1180

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Middle East FZE's KZR Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Kezar Life Sciences (KZR) in Q3 2023, closing a stake of 3,752 shares — an estimated $91.9K sold.

Point72 Middle East FZE first reported a position in KZR in Q1 2023 and held it in 2 quarters. The position peaked at $91.9K in Q2 2023. 82 funds tracked by Wall St. Rank hold KZR as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Kezar Life Sciences position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 3,752 Kezar Life Sciences shares in Q3 2023, an estimated $91.9K.
  • Point72 Middle East FZE first reported a position in Kezar Life Sciences in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Kezar Life Sciences position peaked at $91.9K in Q2 2023.
  • 82 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.